An anti-cancer derivative of butyric acid (pivalyloxymethyl butyrate) and daunorubicin cooperatively prolong survival of mice inoculated with monocytic leukaemia cells
1997

AN-9 and Daunorubicin Help Mice with Leukemia Live Longer

Sample size: 30 publication Evidence: moderate

Author Information

Author(s): T Kasukabe, A Rephaeli, Y Honma

Primary Institution: Saitama Cancer Center Research Institute

Hypothesis

Can the combination of pivalyloxymethyl butyrate (AN-9) and daunorubicin improve survival in mice with monocytic leukaemia?

Conclusion

The combination of AN-9 and daunorubicin significantly prolonged the survival of mice inoculated with monocytic leukaemia cells.

Supporting Evidence

  • AN-9 alone prolonged survival in a dose-dependent manner.
  • Combination treatment with AN-9 and daunorubicin resulted in a significant increase in survival time compared to either treatment alone.
  • AN-9 induced apoptosis in leukaemia cells, while butyrate did not.

Takeaway

Researchers found that a new drug called AN-9, when used with another drug called daunorubicin, helped mice with leukemia live longer.

Methodology

Mice were inoculated with monocytic leukaemia cells and treated with AN-9 and daunorubicin to assess survival times.

Limitations

The study was conducted on mice, and results may not directly translate to humans.

Participant Demographics

Inbred SL strain female mice, aged 8-10 weeks.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication